Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations

NCT02149823 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

92

Enrollment

OTHER

Sponsor class

Stopped All study proceedings stopped prematurely due to Covid-19 restrictions for intranasal formulations

Conditions

Borderline Personality Disorder
BPD
Schizotypal Personality Disorder
SPD
Autism Spectrum Disorder
Schizophrenia
Schizoaffective Disorder
Bipolar Disorder

Interventions

DRUG: Syntocinon 24 Intranasal Units (IU)
DRUG: Syntocinon 40 Intranasal Units (IU)
DRUG: Intranasal Placebo

Sponsor

Maria de las Mercedes Perez Rodriguez

Collaborators

[object Object]
[object Object]